ASCO 2023: Ellipses Pharma advances plans for RET inhibitor following encouraging results
Chicago, Illinois-based Ellipses Pharma has announced its intention to accelerate the global clinical development of its selective RET inhibitor EP0031/A400. Following …
Who’s posting what? Virtual Care related social media posts increased by 21% in the pharma industry in Q1 2023
The global pharma industry experienced a 21% rise in social media posts on virtual care in Q1 2023 compared with …
Who’s posting what? Regenerative Medicine related social media posts increased by 11% in the pharma industry in Q1 2023
The global pharma industry experienced an 11% rise in social media posts on regenerative medicine in Q1 2023 compared with …
Who’s posting what? Orphan Designated Drugs related social media posts increased by 9% in the pharma industry in Q1 2023
The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared …
Who’s posting what? Microbiome related social media posts increased by 0.48% in the pharma industry in Q1 2023
The global pharma industry experienced 0.48% rise in social media posts on microbiome in Q1 2023 compared with the previous …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Who’s posting what? Big Data related social media posts increased by 11% in the pharma industry in Q1 2023
The global pharma industry experienced an 11% rise in social media posts on big data in Q1 2023 compared with …
Risk adjusted net present value: What is the current valuation of ARS Pharmaceuticals’s Neffy?
Neffy is a small molecule commercialized by ARS Pharmaceuticals, with a leading Pre-Registration program in Anaphylaxis. According to Globaldata, it …
Risk adjusted net present value: What is the current valuation of Exelixis’s Zanzalintinib?
Zanzalintinib is a small molecule commercialized by Exelixis, with a leading Phase III program in Metastatic Colorectal Cancer. According to …
Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s SPK-8016?
SPK-8016 is a gene therapy commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Hemophilia A (Factor …
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s MYK-224?
MYK-224 is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Hypertrophic Cardiomyopathy. According to …
Risk adjusted net present value: What is the current valuation of GSK’s LiProSal?
LiProSal is a small molecule commercialized by GSK, with a leading Phase II program in Dementia Associated With Alzheimer's Disease. …
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Remternetug?
Remternetug is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase III program in Alzheimer's Disease. …
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Orforglipron Calcium?
Orforglipron Calcium is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Type …
Risk adjusted net present value: What is the current valuation of Avidity Biosciences’s AOC-1001?
AOC-1001 is a monoclonal antibody conjugated commercialized by Avidity Biosciences, with a leading Phase II program in Myotonic Dystrophy. According …
Risk adjusted net present value: What is the current valuation of Foghorn Therapeutics’s FHD-286?
FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Metastatic Uveal Melanoma. According …